EyePoint Pharmaceuticals Future Growth
Future criteria checks 2/6
EyePoint Pharmaceuticals is forecast to grow earnings and revenue by 2.2% and 42.3% per annum respectively. EPS is expected to grow by 7.1% per annum. Return on equity is forecast to be -68.9% in 3 years.
Key information
2.2%
Earnings growth rate
7.1%
EPS growth rate
Pharmaceuticals earnings growth | 22.3% |
Revenue growth rate | 42.3% |
Future return on equity | -68.9% |
Analyst coverage | Good |
Last updated | 14 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10 | -201 | -122 | -189 | 7 |
12/31/2025 | 12 | -188 | -133 | -151 | 9 |
12/31/2024 | 41 | -128 | -137 | -115 | 7 |
3/31/2024 | 50 | -79 | -17 | -12 | N/A |
12/31/2023 | 46 | -71 | -2 | 2 | N/A |
9/30/2023 | 43 | -100 | 9 | 12 | N/A |
6/30/2023 | 37 | -106 | 12 | 14 | N/A |
3/31/2023 | 40 | -102 | -64 | -62 | N/A |
12/31/2022 | 41 | -102 | -67 | -65 | N/A |
9/30/2022 | 42 | -78 | -71 | -69 | N/A |
6/30/2022 | 41 | -77 | -64 | -64 | N/A |
3/31/2022 | 39 | -67 | -55 | -55 | N/A |
12/31/2021 | 37 | -58 | -50 | -50 | N/A |
9/30/2021 | 33 | -54 | -28 | -28 | N/A |
6/30/2021 | 39 | -42 | -19 | -19 | N/A |
3/31/2021 | 34 | -44 | -14 | -13 | N/A |
12/31/2020 | 34 | -45 | -15 | -14 | N/A |
9/30/2020 | 36 | -40 | -32 | -32 | N/A |
6/30/2020 | 23 | -52 | -48 | -48 | N/A |
3/31/2020 | 26 | -51 | -60 | -60 | N/A |
12/31/2019 | 20 | -57 | -57 | -57 | N/A |
9/30/2019 | 14 | -58 | -56 | -56 | N/A |
6/30/2019 | 12 | -75 | -53 | -53 | N/A |
3/31/2019 | 6 | -98 | -42 | -42 | N/A |
12/31/2018 | 5 | -86 | -34 | -33 | N/A |
9/30/2018 | 3 | -80 | -28 | -28 | N/A |
6/30/2018 | 3 | -53 | -22 | -22 | N/A |
3/31/2018 | 3 | -25 | -20 | -20 | N/A |
12/31/2017 | 3 | -23 | N/A | -20 | N/A |
9/30/2017 | 8 | -17 | N/A | -20 | N/A |
6/30/2017 | 8 | -18 | N/A | -20 | N/A |
3/31/2017 | 7 | -19 | N/A | -20 | N/A |
12/31/2016 | 7 | -19 | N/A | -20 | N/A |
9/30/2016 | 1 | -24 | N/A | -18 | N/A |
6/30/2016 | 2 | -22 | N/A | -16 | N/A |
3/31/2016 | 2 | -20 | N/A | -15 | N/A |
12/31/2015 | 2 | -20 | N/A | -15 | N/A |
9/30/2015 | 2 | -19 | N/A | 10 | N/A |
6/30/2015 | 27 | 6 | N/A | 10 | N/A |
3/31/2015 | 26 | 8 | N/A | 11 | N/A |
12/31/2014 | 28 | 10 | N/A | 13 | N/A |
9/30/2014 | 28 | 11 | N/A | -11 | N/A |
6/30/2014 | 3 | -13 | N/A | -11 | N/A |
3/31/2014 | 4 | -13 | N/A | -11 | N/A |
12/31/2013 | 2 | -14 | N/A | -11 | N/A |
9/30/2013 | 2 | -13 | N/A | -11 | N/A |
6/30/2013 | 2 | -12 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PV3B is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PV3B is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PV3B is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PV3B's revenue (42.3% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: PV3B's revenue (42.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PV3B is forecast to be unprofitable in 3 years.